RuiYi's Autoimmune Treatment Starts Clinical Trial

RuiYi, Inc., a San Diego-Shanghai biotech, has begun a Phase I trial of Gerilimzumab, its novel anti-IL-6 cytokine mAb, as a treatment for autoimmune disorders, especially rheumatoid arthritis. According to RuiYi, the preclinical tests of the drug showed the highest combined subcutaneous bioavailability, potency and blood half-life of any cytokine biologic RA treatment. RuiYi believes a once-monthly regimen is possible. RuiYi in-licensed worldwide rights to Gerilimzumab from ArGEN-X of Belgium in 2012 and then partnered with Genor BioPharma of Shanghai, which is developing the drug for China. More details.... Stock Symbol: (Euronext Brussels: ARGX) Share this with colleagues: // //